Connect Biopharma Holdings Ltd - ADR Aktie News

– Rademikibart reduzierte die Rate von Therapieversagen nach 28 Tagen signifikant um 66 % im Vergleich zu Placebo – – Rademikibart zeigte bereits am Tag 7 eine schnelle, statistisch signifikante Verbesserung der Lungenfunktion gegenüber Placebo – – Rademikibart wurde bei Asthmapatienten mit akuter Exazerbation gut vertragen mit einer niedrigen Inzidenz von unerwünschten Ereignissen – – Daten au...

– Einschreibung in die Phase‑2-Seabreeze-STAT-Studien zu akuten Exazerbationen bei Asthma und COPD abgeschlossen – – Erwartet, die Topline-Ergebnisse aus beiden Phase‑2-Seabreeze-STAT-Studien im September 2026 zu berichten – – Zahlungsmittelbestand voraussichtlich für einen Zeitraum von mindestens einem Jahr ab dem Datum dieser Veröffentlichung ausreichend – SAN DIEGO, 12. Aug. 2026 (GLOBE NEWS...

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharma...

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference o...

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating...

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered...

Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has enter...